Biomarkers in biological fluids for dementia with Lewy bodies

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Schade, Sebastian ^a,b   Mollenhauer, Brit ^a,b  

^a Paracelsus Elena Klinik   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BODY FLUID; CEREBROSPINAL FLUID; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; HUMAN; INCIDENCE; MEDICAL DECISION MAKING; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 84989199444     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0072-3     Document Type: Review

References (95)

1. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D: Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
2. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y: Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004, 19:60-67.
3. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T: Lewy-And Alzheimer-Type pathologies in Parkinson's disease dementia: which is more important? Brain 2011, 134:1493-1505.
4. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Roontiva A, Bauer RJ, Eisen P, Shaw LM, Davatzikos C, Weiner MW, Reiman EM, Morris JC, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative: Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013, 1:65.
5. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, et al: Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005, 65:1863-1872.
6. Molloy S, McKeith IG, O'Brien JT, Burn DJ: The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005, 76:1200-1203.
7. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M: L-Dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004, 63:376-378.
8. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
9. Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144.
10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006, 5:228-234.
11. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O: Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012, 69:98-106.
12. Jellinger KA: Neurobiology of cognitive impairment in Parkinson's disease. Expert Rev Neurother 2012, 12:1451-1466.
13. Mollenhauer B, Schulz-Schaeffer W, Schlossmacher M: Synaptic alpha-synuclein pathology as the likely cause of Parkinson's disease dementia. Lancet Neurol 2011, 10:68-69.
14. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ: Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008, 79:1331-1338.
15. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA: Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.
16. Jokinen P, Scheinin N, Aalto S, Nagren K, Savisto N, Parkkola R, Rokka J, Haaparanta M, Roytta M, Rinne JO: [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010, 16:666-670.
17. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C: Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Ann Neurol 2005, 58:773-776.
18. Kramer ML, Schulz-Schaeffer WJ: Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007, 27:1405-1410.
19. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, Johnson KA, Growdon JH: Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012, 27:965-973.
20. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E: CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010, 81:1080-1086.
21. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E, Ezquerra M, Rios J, Tolosa E: Cerebrospinal tau, phospho-Tau, and beta-Amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009, 24:2203-2210.
22. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J: CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685.
23. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH: Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013, 80:85-91.
24. Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Forland MG, Tysnes OB, Larsen JP, Pedersen KF: CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 2014, 82:1784-1790.
25. Borroni B, Alberici A, Archetti S, Magnani E, Di Luca M, Padovani A: New insights into biological markers of frontotemporal lobar degeneration spectrum. Curr Med Chem 2010, 17:1002-1009.
26. Mak E, Su L, Williams GB, O'Brien JT: Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther 2014, 6:18.
27. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M: EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008, 131:690-705.
28. Terzaghi M, Arnaldi D, Rizzetti MC, Minafra B, Cremascoli R, Rustioni V, Zangaglia R, Pasotti C, Sinforiani E, Pacchetti C, Manni R: Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies. Mov Disord 2013, 28:1416-1423.
29. Braak H, de Vos RAI, Bohl J, Del Tredici K: Gastric [alpha]-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006, 396:67-72.
30. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J: Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011, 134:e178.
31. Glenner GG, Wong CW, Quaranta V, Eanes ED: The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis. Appl Pathol 1984, 2:357-369.
32. Guntert A, Dobeli H, Bohrmann B: High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143:461-475.
33. Jendroska K, Kashiwagi M, Sassoon J, Daniel SE: Amyloid beta-peptide and its relationship with dementia in Lewy body disease. J Neural Transm Suppl 1997, 51:137-144.
34. Kanemaru K, Kameda N, Yamanouchi H: Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000, 54:1875-1876.
35. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
36. Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer WJ, Trenkwalder C, Bibl M, Steinacker P, Kretzschmar HA, Wiltfang J, Otto M: Different CSF beta-Amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm 2011, 118:691-697.
37. Nutu M, Zetterberg H, Londos E, Minthon L, Nagga K, Blennow K, Hansson O, Ohrfelt A: Evaluation of the cerebrospinal fluid amyloid-beta1-42/amyloid-beta1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. Dement Geriatr Cogn Disord 2013, 36:99-110.
38. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Burger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Blaser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E: Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006, 44:1472-1480.
39. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M: Total tau protein, phosphorylated tau (181p) protein, beta-Amyloid(1-42), and beta-Amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 2006, 44:192-195.
40. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ: Cerebrospinal fluid tau and beta-Amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003, 60:1696-1702.
41. Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelborghs S: Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis 2013, 35:137-146.
42. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J: Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007, 12:671-680.
43. Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M: CSF amyloid-beta peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease. J Alzheimers Dis 2011, 24:383-391.
44. Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K: Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis 2009, 6:87-94.
45. Cleveland DW, Spiegelman BM, Kirschner MW: Conservation of microtubule associated proteins. Isolation and characterization of tau and the high molecular weight microtubule associated protein from chicken brain and from mouse fibroblasts and comparison to the corresponding mammalian brain proteins. J Biol Chem1979, 254:12670-12678.
46. Braak H, Braak E, Grundke-Iqbal I, Iqbal K: Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett 1986, 65:351-355.
47. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM: Microtubule-Associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986, 261:6084-6089.
48. Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
49. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, NeumannM, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, OttoM: Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005, 19:164-170.
50. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F: CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001, 22:77-78.
51. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, Thal LJ, Corey-Bloom J: Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003, 60:1586-1590.
52. Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, Ikeda K, Kawai M: Cellular co-localization of phosphorylated tau-And NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999, 843:53-61.
53. Hampel H, Goernitz A, Buerger K: Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull 2003, 61:243-253.
54. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995, 26:231-245.
55. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HJ, Davies P, Hampel H: Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002, 59:1267-1272.
56. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke-Iqbal I, Wang JZ: Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002, 320:156-160.
57. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretzschmar H, Moeller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K: Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001, 50:150-156.
58. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC: Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005, 123:383-396.
59. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
60. Gai WP, Power JH, Blumbergs PC, Blessing WW: Multiple-system atrophy: A new alpha-synuclein disease? Lancet 1998, 352:547-548.
61. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D: Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. Faseb J 2003, 17:1945-1947.
62. Lee HJ, Patel S, Lee SJ: Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005, 25:6016-6024.
63. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J: Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011, 69:570-580.
64. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM: CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2011, 33:430.e1-3.
65. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG: Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010, 4:683-699.
66. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K: The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS One 2013, 8:e81654.
67. Cantuti-Castelvetri I, Klucken J, Ingelsson M, Ramasamy K, McLean PJ, Frosch MP, Hyman BT, Standaert DG: Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 2005, 64:1058-1066.
68. Beyer K, Humbert J, Ferrer A, Lao JI, Carrato C, Lopez D, Ferrer I, Ariza A: Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease. Neuroreport 2006, 17:1327-1330.
69. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ: Phosphorylation of Ser 129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006, 281:29739-29752.
70. Chodobski A, Szmydynger-Chodobska J: Choroid plexus: Target for polypeptides and site of their synthesis. Microsc Res Tech 2001, 52:65-82.
71. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J: CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol 2013, 126:683-697.
72. Mattsson N, Insel P, Tosun D, Zhang J, Jack CR Jr, Galasko D, Weiner M, Alzheimer's Disease Neuroimaging Initiative: Effects of baseline CSF alpha-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. PLoS One 2013, 8:e85443.
73. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J 2006, 20:419-425.
74. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM: Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
75. WennstromM, Surova Y, Hall S, Nilsson C, Minthon L, BostromF, Hansson O, Nielsen HM: Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013, 8:e53250.
76. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T, Hashimoto M: Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006, 345:967-972.
77. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J: DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
78. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI, Chin LS, Li L: Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem2006, 281:10816-10824.
79. de Jong D, Jansen RW, Pijnenburg YA, van Geel WJ, Borm GF, Kremer HP, Verbeek MM: CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 2007, 78:936-938.
80. Ching GY, Liem RK: Assembly of type IV neuronal intermediate filaments in nonneuronal cells in the absence of preexisting cytoplasmic intermediate filaments. J Cell Biol 1993, 122:1323-1335.
81. Schmidt ML, Murray J, Lee VM, Hill WD, Wertkin A, Trojanowski JQ: Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991, 139:53-65.
82. Storch J, Thumser AE: Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 2010, 285:32679-32683.
83. Cheon MS, Kim SH, Fountoulakis M, Lubec G: Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. J Neural Transm Suppl 2003, 67:225-234.
84. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M: Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004, 370:36-39.
85. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M: Serum heart-Type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 2007, 4:366-375.
86. Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM: CSF tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 2011, 27:377-384.
87. Herbert MK, Aerts MB, Kuiperij HB, Claassen JA, Spies PE, Esselink RA, Bloem BR, Verbeek MM: Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Alzheimers Dement 2014, 10:448-455. e442.
88. Nielsen HM, Hall S, Surova Y, Nagga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennstrom M: Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. J Alzheimers Dis 2014, 40:343-350.
89. Schultz K, Wiehager S, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersen A: Reduced CSF CART in dementia with Lewy bodies. Neurosci Lett 2009, 453:104-106.
90. Bostrom F, Hansson O, Gerhardsson L, Lundh T, Minthon L, Stomrud E, Zetterberg H, Londos E: CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. Neurobiol Aging 2009, 30:1265-1271.
91. Ho GJ, Liang W, Waragai M, Sekiyama K, Masliah E, Hashimoto M: Bridging molecular genetics and biomarkers in lewy body and related disorders. Int J Alzheimers Dis 2011, 2011:842475.
92. Wada-Isoe K, Michio K, Imamura K, Nakaso K, Kusumi M, Kowa H, Nakashima K: Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis. J Neural Transm 2007, 114:1579-1583.
93. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J: Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006, 9:293-348.
94. Zhang J: Proteomics of human cerebrospinal fluid-The good, the bad, and the ugly. Proteomics Clin Appl 2007, 1:805-819.
95. Mollenhauer B, Schlossmacher MG: CSF synuclein: Adding to the biomarker footprint of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2010, 81:590-591.